Female hair loss guide: types, causes, and effective treatments

Hair loss affects approximately 40% of women by age 50 — and unlike male pattern baldness, female hair loss is often underdiagnosed, undertreated, and carries significant psychological impact. Here is the complete evidence-based guide.

The three most common types

Female pattern hair loss (FPHL / androgenetic alopecia)

The most common cause of progressive hair thinning in women.

Pattern: Diffuse thinning over the crown and top of the scalp — the "Christmas tree" or central part widening pattern (Ludwig pattern). Unlike men, women rarely develop complete baldness; they maintain the frontal hairline but lose density centrally.

Mechanism: DHT (dihydrotestosterone) — converted from testosterone by 5-alpha-reductase in the follicle — binds androgen receptors in genetically susceptible follicles → follicular miniaturization:
The anagen (growth) phase shortens over successive hair cycles
Hair fibers produced become progressively finer and shorter (vellus-like)
The follicle does not die — it miniaturizes; this is why treatment can restore it if begun early

Important: Women with FPHL often have normal circulating androgen levels — the follicular androgen sensitivity is the issue, not androgen excess. Blood tests for androgens are normal in most women with FPHL.

Who is at risk: Strong genetic component — if a mother or maternal grandmother had thinning hair, risk is significantly elevated. Onset is typically gradual, beginning in the 30s–40s, though it can begin in the 20s.

Telogen effluvium (TE)

Pattern: Diffuse shedding across the entire scalp — not pattern-specific. Patient notices significantly more hair on the brush, shower drain, and pillow. The hair shed is telogen hairs (club hairs with a white root bulb).

Mechanism: A systemic stress causes a large proportion of anagen follicles to simultaneously shift to the telogen (resting) phase → 2–3 months later, the telogen hairs shed together as the new anagen hair pushes them out. The shedding appears 2–3 months after the triggering event.

Common triggers:
Postpartum (the most common TE) — estrogen during pregnancy prolongs anagen; the drop postpartum triggers synchronized telogen shift
Significant weight loss or calorie restriction
Surgery or major illness
Thyroid dysfunction (hypo- and hyperthyroidism)
Iron deficiency (even without anemia)
Chronic stress
Stopping oral contraceptive pills
COVID-19 illness

Prognosis: Acute telogen effluvium resolves spontaneously over 6–9 months once the trigger resolves. Chronic telogen effluvium (>6 months duration) requires identification and correction of the ongoing trigger.

Alopecia areata (AA)

Pattern: Sharply demarcated, smooth oval or round patches of hair loss — completely bald within the patch, with normal skin. May be single or multiple patches; rarely progresses to total scalp (alopecia totalis) or body (alopecia universalis) hair loss.

Mechanism: Autoimmune — cytotoxic T cells target the follicular bulge and bulb; the hair follicle loses its immune privilege (normally protected from immune attack). JAK1/JAK3 signaling drives the T-cell activity against follicles.

Markers: "Exclamation mark hairs" at the patch border (tapered at the base); nail pitting (20–50% of patients); family history of autoimmune thyroid disease.

Treatment: Topical/intralesional/oral corticosteroids; contact sensitizers (DPCP); baricitinib (Olumiant) and ritlecitinib (Litfulo) — JAK inhibitors FDA-approved for severe alopecia areata — represent the first targeted therapies for this condition.

---

Differential diagnosis workup

Key distinguishing features

| Feature | FPHL | Telogen Effluvium | Alopecia Areata |
|---|---|---|---|
| Pattern | Crown thinning, central part | Diffuse | Patchy, focal |
| Shedding | Gradual | Acute shedding | Hair shed from patches |
| Hairline | Preserved | Preserved | Preserved (in patches) |
| Onset | Years | Weeks–months | Weeks |
| Trigger | None (genetic) | Identifiable stress | Autoimmune |
| Pull test | Negative | Positive (>6 hairs) | Positive at patch margin |

Blood tests to consider

For any significant hair loss, the following labs help exclude correctable systemic causes:

CBC — iron deficiency anemia; platelet disorders
Ferritin — iron stores; ferritin &lt;30 ng/mL is associated with TE even without anemia; optimal ferritin for hair growth is thought to be >70–80 ng/mL
TSH — thyroid dysfunction (both hypo and hyperthyroidism cause TE)
Total testosterone + DHEA-S — if signs of androgen excess (hirsutism, irregular periods, acne)
Prolactin — if cycle irregularity present
Zinc — deficiency causes diffuse TE
Vitamin D — deficiency associated with TE in some studies (correlation, not proven causation)
ANA — if alopecia areata or lupus-related hair loss suspected

---

Evidence-based treatments

Minoxidil (topical)

The only FDA-approved topical treatment for female pattern hair loss.

Mechanism: Minoxidil is a potassium channel opener — in the scalp, it increases blood flow to follicles and prolongs the anagen (growth) phase. The active form is minoxidil sulfate, converted by sulfotransferase enzymes in follicular cells. Individuals with low scalp sulfotransferase activity ("poor converters") respond minimally to topical minoxidil.

Forms for women:
2% solution or 5% foam — FDA-approved; the 5% foam is approved for women (the 5% solution carries a hypertrichosis risk in women from systemic absorption; the foam has lower absorption)
Apply to a dry scalp at the area of thinning, once or twice daily
Must be used continuously — stopping causes resumption of miniaturization

Evidence: Olsen 2002 (RCT, 381 women): 5% minoxidil foam produced significantly greater improvement in hair density than 2% solution at 24 weeks. Gupta 2014 (meta-analysis): 2% topical minoxidil produced statistically significant hair count improvement vs. placebo across all included trials.

Timeline: Initial shedding increase in the first 2–6 weeks (telogen hair displacement by new anagen — a good sign). Visible improvement at 4–6 months; full response assessment at 12 months.

Oral minoxidil (low-dose)

Low-dose oral minoxidil (0.25–1 mg/day for women) has emerged as an increasingly used option — avoids the scalp irritation and inconvenience of topical application, and delivers minoxidil systemically (bypasses the sulfotransferase conversion variability of topical).

Evidence: Ramos 2020 (retrospective, 100 women): Low-dose oral minoxidil 1 mg/day produced significant hair density improvement in FPHL and TE with good tolerability. Main side effects: mild hypertrichosis (fine body hair in some patients), fluid retention (rare at low doses), cardiac considerations in patients with underlying cardiovascular disease.

Spironolactone

An aldosterone antagonist that also blocks androgen receptors — reduces DHT action at the follicle in androgen-sensitive FPHL.

Dose for hair loss: 100–200 mg/day (higher than doses used for acne). Requires blood pressure monitoring and potassium level checks (can cause hyperkalemia).

Evidence: Sinclair 2011 (prospective, 80 women with FPHL): 40% of patients on spironolactone 200 mg/day showed hair density improvement; 44% stabilization. Less robust RCT data than minoxidil; used off-label.

Contraindications: Pregnancy (teratogenic — potassium-sparing diuretics feminize male fetuses); requires reliable contraception.

Finasteride (off-label in women)

5-alpha-reductase inhibitor — reduces DHT production. Well-established in male pattern baldness; used off-label in post-menopausal women.

Not used in premenopausal women without reliable contraception — teratogenic (feminization of male fetuses).

Evidence: Iorizzo 2006 (RCT, post-menopausal women): finasteride 1 mg/day produced modest improvement in hair density over 12 months in FPHL.

PRP (platelet-rich plasma)

Autologous PRP injected into the scalp delivers concentrated growth factors (PDGF, VEGF, EGF, IGF-1) that stimulate follicular cells and prolong anagen.

Evidence: Cervantes 2020 (meta-analysis, 460 patients): PRP produced statistically significant improvements in hair count and thickness vs. baseline; most studies not placebo-controlled (difficult to blind intradermal injections). Considered an adjunct rather than standalone therapy.

Protocol: Monthly sessions for 3 months; maintenance every 4–6 months. Results plateau with ongoing maintenance.

Low-level laser therapy (LLLT)

FDA-cleared devices (laser combs, helmets) delivering 650 nm laser light to the scalp — the same photobiomodulation mechanism as red LED. Modest evidence for FPHL.

Jimenez 2014 (RCT): Laser comb 655 nm used 3× weekly for 26 weeks produced significant improvement in hair count vs. sham device. Modest effect size; requires ongoing use.

---

When to see a dermatologist or trichologist

Any acute, rapid shedding lasting >3 months without a clear trigger
Patchy hair loss (evaluate for alopecia areata, scarring alopecias)
Signs of scalp inflammation, scarring, or follicular plugging (lichen planopilaris, frontal fibrosing alopecia — irreversible scarring alopecias where early treatment preserves remaining follicles)
No response to 12 months of minoxidil
Concern about FPHL before age 30

---

Looking for a hair loss consultation or PRP treatment? Browse med spa providers on MedSpot →